Investigational drug · Phase 3
matched to semaglutide
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Overweight, Obesity, Diabetes Mellitus, Type 2.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
94
Any phase or sponsor naming "matched to semaglutide"
First trial start
2026
May 20, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "matched to semaglutide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Overweight
- Obesity
- Diabetes Mellitus, Type 2
Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "matched to semaglutide" as an intervention, largest first.
- REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05669755 · 7,101 participants · Start Mar 1, 2023 · Primary completion Sep 1, 2027
Drug: Cagrilintide; Semaglutide and 1 more · For: Cardiovascular Disease
Sites: Birmingham, Alabama; Montgomery, Alabama; Scottsdale, Arizona · 633 sites in all
- A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05567796 · 3,400 participants (planned) · Start Nov 1, 2022 · Primary completion Oct 30, 2024
Drug: Cagrilintide; Semaglutide and 2 more · For: Obesity
Sites: Birmingham, Alabama; Los Angeles, California; Aurora, Colorado · 256 sites in all
- Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT01720446 · 3,297 participants · Start Feb 21, 2013 · Primary completion Mar 15, 2016
Drug: semaglutide; semaglutide and 1 more · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Chandler, Arizona; Anaheim, California · 253 sites in all
- A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06065540 · 2,734 participants · Start Sep 27, 2023 · Primary completion Nov 19, 2025
Drug: Cagrilintide; Semaglutide and 2 more · For: Type 2 Diabetes Mellitus
Sites: Birmingham, Alabama; Pelham, Alabama; Phoenix, Arizona · 405 sites in all
- STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or ObesityPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03548935 · 1,961 participants · Start Jun 4, 2018 · Primary completion Mar 30, 2020
Drug: Semaglutide; Placebo (semaglutide) · For: Metabolism and Nutrition Disorder; Overweight or Obesity
Sites: Anniston, Alabama; Anaheim, California; Lomita, California · 128 sites in all
- A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)Pivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05646706 · 1,407 participants · Start Jan 4, 2023 · Primary completion Oct 30, 2024
Drug: Semaglutide; Semaglutide and 1 more · For: Obesity
Sites: Birmingham, Alabama; Montgomery, Alabama; Walnut Creek, California · 107 sites in all
- Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have DiabetesPivotal-lookingActive, not recruiting
KaileraIndustry
NCT07284979 · 1,270 participants · Start Dec 30, 2025 · Primary completion Mar 2028
Drug: Ribupatide; Semaglutide and 1 more · For: Obesity
Sites: Glendale, Arizona; Phoenix, Arizona; Little Rock, Arkansas · 60 sites in all
- Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or ObesityPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03552757 · 1,210 participants · Start Jun 4, 2018 · Primary completion Mar 24, 2020
Drug: Semaglutide 1.0 mg; Semaglutide 2.4 mg and 2 more · For: Obesity; Overweight
Sites: Buena Park, California; Concord, California; Fresno, California · 147 sites in all
- AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or BothPivotal-lookingNot yet recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07931573 · 1,200 participants (planned) · Start Nov 10, 2026 · Primary completion Jul 4, 2028
Drug: Zenagamtide; Semaglutide and 1 more · For: Type 2 Diabetes
Sites: Phoenix, Arizona; La Jolla, California; La Mesa, California · 230 sites in all
- Validation & Intervention Testing for Aging, Longevity and HealthspanPivotal-lookingNot yet recruiting
The University of Texas Health Science Center at San AntonioAcademic, hospital or other
NCT07923630 · 1,200 participants (planned) · Start Jan 2027 · Primary completion Dec 2030
Drug: Dapagliflozin 10Mg Oral Tablet; Semaglutide oral · For: Aging; Functional Decline
Sites: San Antonio, Texas · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Overweight
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novo Nordisk.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.